Article PDF first page preview

First page of High ultra-processed food consumption is associated with clinical exacerbation in patients with Crohn's disease in remission - a prospective cohort study

Introduction: Diet can impact the clinical course of Crohn’s disease (CD). However, the importance of food processing level is uncertain. We aimed to evaluate whether ultra-processed foods (UPFs) are associated with an increased risk of relapse amongst patients with CD in clinical remission. Methods: In this prospective cohort study, adult patients with CD in clinical remission, were followed for one year or until clinical relapse, as assessed by the Harvey Bradshaw index. Dietary intake was assessed using a food frequency questionnaire and a dedicated validated processed food questionnaire to evaluate UPFs consumption. Multivariable Cox proportional hazard models were used to estimate the adjusted hazard ratio of disease relapse according to high or low UPFs consumption. Results: A total of 111 patients with CD (mean age 37.9±14.0 years) in clinical remission were followed. Over a median period of 12 months [interquartile range, 8-12], 24 patients (21.6%) experienced clinical relapse. Fecal calprotectin levels were increased at relapse visit compared to baseline (193.0 μg/g [114.0-807.0], 79.0 μg/g [17.0-274.5], respectively, P=0.002). A higher intake of UPFs was associated with an increased risk of CD relapse (HR=3.86, 95% CI 1.30-11.47). Ultra-processed breads and pastries, as well as oils and spreads, were the UPF subgroups with the strongest positive associations (HR=3.27, 95% CI 1.26-8.45; HR=2.76, 95% CI 1.02-7.45, respectively). Conclusion: UPFs consumption is associated with an increased risk of relapse in patients with CD in remission. This study, along with future research, can contribute to establishing nutritional guidelines aimed to reduce UPFs consumption in this population.

The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial